Evercore ISI Group maintained its 'Outperform' rating on Altimmune but slightly lowered its price target from $18 to $17. This indicates a continued positive outlook on the company's fundamentals, though with a minor adjustment to its valuation expectations. The market impact is likely moderate, as the rating remains positive despite the small price target reduction.
Evercore ISI Group's analyst Liisa Bayko maintained an 'Outperform' rating on Altimmune (ALT) but reduced the price target from $18 to $17. This action signals that while the analyst still views Altimmune favorably, there might be minor adjustments to their valuation model or near-term expectations. For traders, this is a neutral to slightly negative signal in the short term due to the price target reduction, but the maintained 'Outperform' rating suggests long-term confidence. The primary impact is on investor sentiment and potentially minor price fluctuations for ALT, as the core investment thesis remains intact.